Rising obesity rates are driving an epidemic of obesity-related OSA while access to care from a sleep specialist is limited. The SURMOUNT-OSA studies investigated tirzepatide as a treatment option for moderate to severe OSA with obesity. If approved as a treatment option, non-sleep specialists caring for patients with obesity and OSA will need to assess risk and develop care plans based on shared decision making. Equipping obesity medicine and primary care clinicians with the knowledge and skills to diagnose and manage people living with OSA and obesity would help to address this unmet need. This session aims to use case-based discussion to address real-world practice clinical considerations when using tirzepatide in people with OSA and obesity. CME/CE Expiration Date: 4/27/28 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 7173 S. Havana St #600-130
Pricing
CME included with membership · $2,000–3,000/yr
| Individual Course (pay-per-activity) | $21 |
| All Access Pass – OMA Member | $2,000/yr |
| All Access Pass – Non-Member | $3,000/yr |
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Cardiovascular Disease
- Child & Adolescent Psychiatry
- Clinical Informatics
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Comprehensive & Board Review
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Health Equity & Inclusion
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurodevelopmental Disabilities
- Obstetrics & Gynecology
- Orthopaedic Surgery
- Patient Safety & Quality Improvement
- Physical Medicine & Rehabilitation
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Preventive Medicine
- Primary Care Sports Medicine
- Sleep Medicine
- Transplant Hepatology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Orthopedics
- Pediatrics
- Primary care
- Psychiatry
- Rehabilitation
- Sports & Exercise Medicine
- Surgery
- No reviews yet. Be the first to share yours.
- On-demand / recorded video
- includes Case-based learning
- Credit · Up to 1 credit
- MOC · Up to 1 point
- $31.25
-
ReleasedApr 27, 2025
-
Last day to claim creditApr 28, 2028 2 years left
-
American College of Physicians Annals On Call – Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
-
American College of Physicians Annals On Call – Tirzepatide Versus Intensified Conventional Care for Poorly Controlled Type 2 Diabetes
-
Medical Letter, The 1765: Influenza Vaccination Recommendations, Tirzepatide for CV Risk Reduction, New Drugs for Breast Cancer, Melanoma, and Hearing Loss
-
Obesity Medicine Association Obesity Medicine 2024 – Tirzepatide Global Trials and Efficacy Insights (Recorded)
-
Obesity Medicine Association Overcoming Obesity 2023 – Safety and Efficacy of Tirzepatide for Chronic Weight Management: SURMOUNT-1 and SURMOUNT-2 (Recorded)
-
Obesity Medicine Association Overcoming Obesity 2023 – Pharmacotherapy for Medically Complicated Obesity: A Case-Based Approach (Recorded)
